行情

CLBS

CLBS

Caladrius
NASDAQ

实时行情|Nasdaq Last Sale

1.795
+0.134
+8.09%
交易中 11:46 04/02 EDT
开盘
1.720
昨收
1.661
最高
1.795
最低
1.663
成交量
578
成交额
--
52周最高
3.683
52周最低
1.050
市值
1,909.66万
市盈率(TTM)
-0.9577
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CLBS价格均价为10.50,最高价位18.50,最低价为6.00。

EPS

CLBS 新闻

更多
  • 五大专家点评瑞幸造假 瑞幸咖啡或将被强制退市
  • 新浪财经 · 1小时前
  • 早盘:美股涨幅扩大 道指上涨450点
  • 新浪美股 · 1小时前
  • 被指牵头伪造交易22亿 致瑞幸股价雪崩的刘剑是谁?
  • 虎嗅APP · 1小时前
  • 杨德龙:瑞幸伪造交易22亿暴跌80% 小心8种成长陷阱
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
+2.30%
制药与医学研究
+1.47%

热门股票

代码
价格
涨跌幅

CLBS 简况

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. It also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.
展开

微牛提供Caladrius Biosciences Inc(NASDAQ-CLBS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CLBS股票新闻,以帮助您做出投资决策。